Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07286058 · ClinicalTrials.gov registry record · Phase 3
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
A Phase 3 study of Psoriatic Arthritis, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,182
- Enrollment target
- 1
- Study location
NCT07286058: Recruiting Phase 3 study of Psoriatic Arthritis, sponsored by Takeda.
NCT07286058 is a Phase 3 study of Psoriatic Arthritis that is actively recruiting participants, run by Takeda. The registered enrollment target is 1,182 participants, above the 828-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (43% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07286058, a Phase 3 study of Psoriatic Arthritis, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,182 participants
- Enrollment target
- 1
- Study location
Study Summary
Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin. The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over a longer period of time. Adults who completed the 1-year (52-week) treatment period in one of the parent studies (TAK-279-PsA-3001 \[NCT06671483\] or TAK-279-PsA-3002 \[NCT06671496\]) may be able to join this continuation study (also called long-term extension or LTE study). All participants in this continuation study, will receive zasocitinib (lower or higher dose), once a day (QD). Each participant can be in this study for approximately 2 years (108 weeks). This includes a treatment period of up to 2 years (104 weeks) and a 1-month (4-week) follow-up period to monitor a participant's health.
Primary Outcome
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the trial intervention, whether or not the occurrence is considered related to the trial intervention. TEAE is defined as any AE emerging or manifesting at or after the initiation of treatment in the LTE study with a trial intervention or medicinal product or any existing AE that worsens in either intensity or frequency following exposure to the trial intervention or me
Conditions Studied
Interventions
- DRUG Zasocitinib
Study Locations (1)
California
- First OC Dermatology Research Inc. - Fountain Valley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,182 participants |
| Start Date | 2026-03-11 |
| Est. Completion | 2029-12-18 |
| Phase | Phase 3 |
What NCT07286058 shows while recruiting
NCT07286058 is an interventional study that assigns participants to a tested intervention. Its 1,182 participants enrollment target places it among the larger protocols in the corpus, above the 828-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (43% higher).
The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Zasocitinib is the first listed.
NCT07286058 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07286058 about?
NCT07286058 is a clinical study titled "Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis". Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin. The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over a longer period of time. Adults who completed the 1-year (52-week) t...
What is the current status of trial NCT07286058?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,182 participants. The study started on 2026-03-11. Estimated completion is 2029-12-18.
What conditions does trial NCT07286058 study?
This clinical trial studies the following conditions: Psoriatic Arthritis.
What interventions are being tested in trial NCT07286058?
The interventions under investigation include: Zasocitinib (DRUG).
Who is sponsoring clinical trial NCT07286058?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07286058 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07286058's enrollment target sits among peer trials
1,182 4th of 48 higher than 45 of 48 other Psoriatic Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriatic Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
RECRUITING · Phase 3
-
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
RECRUITING · Phase 3
-
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04293562 · 1,186 participants · Phase 3
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- NCT05688436 · 1,178 participants
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
- NCT06931275 · 1,178 participants · NA
Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes
- NCT05580419 · 1,188 participants · NA
Impact of 4PCP on Practitioner and Patient Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI